Core Points - Liaoning Chengda Biotechnology Co., Ltd. was established as a joint-stock company in accordance with the Company Law and other relevant regulations [1] - The company completed its initial public offering of 41.65 million shares on October 28, 2021, after approval from the Shanghai Stock Exchange [1][3] - The registered capital of the company is RMB 416.45 million [1] - The company is committed to the research, development, production, and promotion of biological products, adhering to the core values of integrity, responsibility, and quality control [1][2] Company Structure and Governance - The company is governed by a board of directors, with the chairman serving as the legal representative [1] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with its entire assets [1] - The company has established procedures for external guarantees and related party transactions, requiring board or shareholder approval [1][2] Share Issuance and Management - The company's shares are issued in the form of stocks, with each share having a par value of RMB 1 [3][5] - The total number of shares issued at the time of establishment was 360 million, with the current total being 41.65 million shares [5] - The company has specific regulations regarding the increase, decrease, and repurchase of shares, requiring shareholder approval for significant transactions [5][6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company decisions, as well as the right to inspect company documents [9][10] - The company must hold annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [25][26] - Shareholders holding more than 3% of shares for over 180 days can request access to the company's accounting records [10] Financial Management and Transactions - The company must submit significant transactions, including guarantees and financial assistance, for shareholder approval [51][52] - Transactions involving related parties that exceed certain thresholds require evaluation and approval [53][54] - The company is prohibited from providing financial assistance for the acquisition of its shares, except under specific conditions [5][6]

Core Points - The document outlines the working rules for the independent director special meetings of Liaoning Chengda Biological Co., Ltd, aiming to enhance corporate governance and protect the interests of minority shareholders and creditors [1][2] - Independent directors are defined as those who do not hold other positions in the company and have no direct or indirect interests that could affect their independent judgment [1][2] - The company is required to hold at least one independent director special meeting annually, with provisions for additional meetings as needed [2][3] Group 1 - The independent director special meeting is convened by a majority of independent directors and requires their presence to proceed [2][3] - Specific matters that must be discussed in these meetings include decisions related to company acquisitions and other significant issues as stipulated by laws and regulations [2][3] - Independent directors have the authority to independently hire intermediaries for audits or consultations and can propose the convening of temporary shareholder meetings [3][4] Group 2 - The meetings must document key discussion points, including related party transactions and any changes to commitments by the company or related parties [4][5] - The company is responsible for providing necessary conditions for the meetings, including operational data and support for independent directors to conduct site visits [5][6] - Confidentiality obligations are imposed on all attending independent directors regarding the matters discussed in the meetings [6]

辽宁成大生物股份有限公司 关联交易管理制度 辽宁成大生物股份有限公司 关联交易管理制度 第一章 总 则 第一条 为进一步加强辽宁成大生物股份有限公司（以下简称"本公司"或 "公司"）的关联交易管理，明确管理职责和分工，维护公司股东和债权人的合 法权益，特别是中小投资者的合法权益，保证公司与关联方之间订立的关联交易 合同符合公平、公开、公正的原则，依据《中华人民共和国公司法》《中华人民 共和国证券法》（以下简称"《证券法》"）《上海证券交易所科创板股票上市 规则》（以下简称"《上市规则》"）《上海证券交易所上市公司自律监管指引 第5号——交易与关联交易》及其他有关法律、法规规定和《辽宁成大生物股份 有限公司章程》（以下简称"《公司章程》"）的规定，制订本制度。 第二条 公司关联交易的决策管理、信息披露等事项，应当遵守本制度。 第三条 公司处理关联交易事项应当遵循下列原则： (一) 符合诚实信用的原则，保证关联交易的合法性、必要性、合理性和公 允性； (二) 公司与关联人之间的关联交易应签订书面协议，协议的签订应遵循平 等、自愿、等价、有偿的原则； (三) 关联董事、关联股东，在就该关联交易相关事项进行表决时，应 ...

Core Viewpoint - The Chinese livestock industry is experiencing a phase of high pig production capacity, prompting the Ministry of Agriculture and Rural Affairs to implement comprehensive production capacity regulation to mitigate risks of price volatility and overproduction [1][2]. Group 1: Market Performance - As of August 12, 2025, the CSI Livestock Breeding Index (930707) increased by 0.68%, with notable gains from companies such as Xiaoming Co. (300967) up 6.50%, Minhe Co. (002234) up 6.19%, and Yisheng Co. (002458) up 3.28% [1]. - The Livestock ETF (159867) rose by 0.46%, marking its third consecutive increase, with the latest price at 0.65 yuan [1]. Group 2: Policy and Regulation - The Ministry of Agriculture and Rural Affairs has announced plans to guide the reduction of approximately 1 million breeding sows to prevent production fluctuations and price instability [1]. - A meeting held on July 23 emphasized strict implementation of production capacity regulation measures, including the rational elimination of breeding sows and control of new production capacity [1]. Group 3: Industry Outlook - Recent policies are expected to accelerate the elimination of inefficient production capacity in the industry, potentially leading to a long-term increase in pig prices, benefiting low-cost and high-quality pig enterprises [1]. - The top ten weighted stocks in the CSI Livestock Breeding Index account for 64.83% of the index, indicating a concentrated market structure [2].

Core Insights - The report highlights the importance of CFOs in listed companies, revealing that the total salary scale for CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] Salary Distribution - The salary distribution shows that the largest proportion of CFOs earn between 500,000 and 1 million yuan, accounting for 31%, followed by those earning between 300,000 and 500,000 yuan at 27%, and those earning between 1 million and 2 million yuan at 21% [5] - Only 4 CFOs earn over 2 million yuan, representing 5% of the total, while 14 CFOs earn between 100,000 and 300,000 yuan, making up 16% [6] Age and Education - The age distribution indicates that the majority of CFOs are between 40 and 50 years old, comprising 43% of the total, while those aged 50 and above account for 42%. CFOs aged 30 to 40 represent only 15% [1] - In terms of education, 48% of CFOs hold a bachelor's degree, 37% have a master's degree, and 16% have an associate degree [3] Salary Changes - Last year, 67% of CFOs saw their salaries increase, with the highest increase recorded by Yang Shaolin from Haida Group, whose salary rose by 2.27 million yuan to 4.26 million yuan [8] - Conversely, 28% of CFOs experienced a salary decrease, with the largest drop seen in Wang Yonghong from Zhengbang Technology, whose salary fell from 2.20 million yuan to 586,000 yuan [8] Industry Insights - In the agriculture, forestry, animal husbandry, and fishery sector, 22 CFOs earned over 1 million yuan, with 5 companies having revenue exceeding 100 billion yuan [6] - Among the pet food companies, CFO salaries are relatively high, with Xiao Mingyan from Zhongchong Co. earning 1.85 million yuan, while the lowest salary in this sector was 197,800 yuan [9]

Summary of Key Points Core Viewpoint - The report highlights the salary trends and demographic characteristics of CFOs in A-share listed companies for 2024, indicating a total salary scale of 4.27 billion yuan and an average annual salary of 814,800 yuan. Group 1: Salary Overview - The total salary of CFOs in A-share listed companies reached 4.27 billion yuan, with an average annual salary of 814,800 yuan [1] - The highest salary recorded was 4.26 million yuan for Yang Shaolin, CFO of Haida Group, with a significant increase of 2.27 million yuan from the previous year [6] - 67% of CFOs experienced salary increases last year, while 28% saw declines [8] Group 2: Industry Breakdown - In the agriculture, forestry, animal husbandry, and fishery sector, the average salary for CFOs was 787,100 yuan, which is below the market average [1] - Among 22 CFOs in the agriculture, forestry, animal husbandry, and fishery sector, 5 had salaries exceeding 1 million yuan [6] - Companies with revenue exceeding 100 billion yuan had CFOs with higher salaries, while smaller companies had lower compensation [6] Group 3: Demographics - The majority of CFOs are aged between 40 and 50 years, accounting for 43% of the total [1] - The educational background shows that 48% of CFOs hold a bachelor's degree, while 37% have a master's degree [3] - The youngest CFO is 32 years old, while the oldest is 63 years old [1] Group 4: Salary Distribution - The most common salary range for CFOs is between 500,000 and 1 million yuan, making up 31% of the total [5] - There are 4 CFOs with salaries exceeding 2 million yuan, representing 5% of the total [5] - The lowest salary recorded was 150,000 yuan for a CFO in the agriculture sector [6]

Market Overview - The animal health sector increased by 1.46% on August 5, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3617.6, up 0.96%, while the Shenzhen Component Index closed at 11106.96, up 0.59% [1] Stock Performance - Shenlian Biological (688098) closed at 8.83, up 10.79% with a trading volume of 410,700 shares and a turnover of 348 million yuan [1] - Xianfeng Holdings (002141) closed at 3.81, up 4.10% with a trading volume of 732,700 shares and a turnover of 280 million yuan [1] - Jinhai Biological (002688) closed at 7.60, up 3.54% with a trading volume of 645,200 shares and a turnover of 487 million yuan [1] - Huisheng Biological (300871) closed at 24.82, up 1.85% with a trading volume of 260,400 shares and a turnover of 636 million yuan [1] Capital Flow - The animal health sector saw a net inflow of 138 million yuan from institutional investors, while retail investors experienced a net outflow of 127 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors showing confidence while retail investors are withdrawing [2] Individual Stock Capital Flow - Jinhai Biological had a net inflow of 40.62 million yuan from institutional investors, while retail investors had a net outflow of 29.52 million yuan [3] - Huisheng Biological saw a net inflow of 36.65 million yuan from institutional investors, but a significant outflow of 74.58 million yuan from retail investors [3] - Shenlian Biological experienced a net inflow of 18.09 million yuan from institutional investors, with retail investors withdrawing 20.78 million yuan [3]

Group 1 - The animal vaccine sector experienced a decline of 0.39% as of the market close on August 4, ranking among the top losers in concept sectors [1][2] - Within the animal vaccine sector, notable declines were observed in stocks such as Kexing Pharmaceutical, Shenlian Biological, and Kanghua Biological, while 11 stocks saw price increases, with notable gains from Biological Shares, Jinhai Biological, and Weilan Biological, which rose by 2.70%, 2.51%, and 2.10% respectively [1][2] - The animal vaccine sector faced a net outflow of 45 million yuan in principal funds today, with 14 stocks experiencing net outflows, led by Kanghua Biological with a net outflow of 34.6 million yuan [2][3] Group 2 - The top gainers in the concept sectors today included the military equipment restructuring concept, which rose by 5.68%, and military-civilian integration, which increased by 3.53% [2] - The stocks with the highest net inflows in the animal vaccine sector included Jinhai Biological, Guoyao Modern, and Biological Shares, with net inflows of 53.99 million yuan, 11.44 million yuan, and 9.32 million yuan respectively [2][3] - The stock Kanghua Biological had a trading volume turnover rate of 6.20% and a price drop of 2.67%, indicating significant trading activity despite the decline [3]

Market Overview - The animal health sector increased by 0.65% on August 4, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Stock Performance - BioShares (600201) closed at 8.75, rising by 2.70% with a trading volume of 327,100 shares and a turnover of 280 million yuan [1] - Jinhe Biology (002688) closed at 7.34, up 2.51%, with a trading volume of 666,900 shares and a turnover of 485 million yuan [1] - Ruipu Biology (300119) closed at 21.58, increasing by 1.27%, with a trading volume of 72,800 shares and a turnover of 155 million yuan [1] - KQ Biology (688526) closed at 17.00, up 1.01%, with a trading volume of 29,600 shares and a turnover of 49.88 million yuan [1] - Other notable stocks include Dayu Biology (871970) at 10.40 (+0.97%) and Zeng Caike (603566) at 15.00 (+0.87%) [1] Capital Flow - The animal health sector saw a net inflow of 68.12 million yuan from institutional investors, while retail investors experienced a net outflow of 58.45 million yuan [2] - The main capital inflow and outflow for specific stocks include: - Jinhe Biology: 70.12 million yuan inflow from main investors, 33.36 million yuan outflow from retail investors [3] - BioShares: 15.45 million yuan inflow from main investors, 8.61 million yuan outflow from retail investors [3] - Shilian Biology (688098): 3.79 million yuan inflow from main investors, 27.89 million yuan outflow from retail investors [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 关于持股5%以上股东权益变动触及1%刻度的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 证券代码：600201 证券简称：生物股份 公告编号：临2025-048 金宇生物技术股份有限公司 ■ 三、 其他说明 本次权益变动系股东持股比例被动增加，不会对公司治理结构及持续经营产生重大影响。根据《中华人 民共和国证券法》《上市公司收购管理办法》《上市公司股份回购规则》等有关规定，本次权益变动不 涉及信息披露义务人披露权益变动报告书、收购报告书摘要、要约收购报告书摘要等后续工作。 特此公告。 2.信息披露义务人信息 ■ 3、一致行动人信息 ■ 二、权益变动触及1%刻度的基本情况 本次权益变动源于金宇生物技术股份有限公司（以下简称"公司 "）于 2025 年 7 月 31 日注销2023年员 工持股计划已授予但尚未解锁的权益份额对应标的股票862.14万股，公司总股本减少，导致第一大股东 内蒙古金 ...